CA2654839A1 - Utilisation de l'enoxaparine pour reduire le risque de mortalite chez les patients gravement malades - Google Patents

Utilisation de l'enoxaparine pour reduire le risque de mortalite chez les patients gravement malades Download PDF

Info

Publication number: CA2654839A1
Authority: CA; Canada
Prior art keywords: enoxaparin; patients; use according; death; risk
Prior art date: 2009-02-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA2654839A

Other languages

English (en)

Inventor

Bruno Deslandes

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Aventis Pharma SA

Original Assignee

Aventis Pharma SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-02-20

Filing date

2009-02-20

Publication date

2010-08-20

2009-02-20 Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA

2009-02-20 Priority to CA2654839A priority Critical patent/CA2654839A1/fr

2010-08-20 Publication of CA2654839A1 publication Critical patent/CA2654839A1/fr

Status Abandoned legal-status Critical Current

Links

HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 title claims abstract description 68
229960000610 enoxaparin Drugs 0.000 title claims abstract description 41
230000034994 death Effects 0.000 title claims abstract description 25
231100000517 death Toxicity 0.000 title claims abstract description 25
238000011282 treatment Methods 0.000 claims description 26
206010014522 Embolism venous Diseases 0.000 claims description 20
208000004043 venous thromboembolism Diseases 0.000 claims description 20
230000001154 acute effect Effects 0.000 claims description 18
206010028980 Neoplasm Diseases 0.000 claims description 12
201000011510 cancer Diseases 0.000 claims description 12
230000003466 anti-cipated effect Effects 0.000 claims description 6
230000003862 health status Effects 0.000 claims description 6
208000015181 infectious disease Diseases 0.000 claims description 6
230000002829 reductive effect Effects 0.000 claims description 6
206010019280 Heart failures Diseases 0.000 claims description 5
208000019693 Lung disease Diseases 0.000 claims description 5
208000008589 Obesity Diseases 0.000 claims description 5
238000002512 chemotherapy Methods 0.000 claims description 5
230000001684 chronic effect Effects 0.000 claims description 5
235000020824 obesity Nutrition 0.000 claims description 5
230000009885 systemic effect Effects 0.000 claims description 5
238000012337 thromboprophylaxis Methods 0.000 claims description 4
230000007170 pathology Effects 0.000 claims description 3
229960005153 enoxaparin sodium Drugs 0.000 description 19
229940127215 low-molecular weight heparin Drugs 0.000 description 19
CIJQTPFWFXOSEO-NDMITSJXSA-J tetrasodium;(2r,3r,4s)-2-[(2r,3s,4r,5r,6s)-5-acetamido-6-[(1r,2r,3r,4r)-4-[(2r,3s,4r,5r,6r)-5-acetamido-6-[(4r,5r,6r)-2-carboxylato-4,5-dihydroxy-6-[[(1r,3r,4r,5r)-3-hydroxy-4-(sulfonatoamino)-6,8-dioxabicyclo[3.2.1]octan-2-yl]oxy]oxan-3-yl]oxy-2-(hydroxy Chemical compound [Na+].[Na+].[Na+].[Na+].O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1O)NC(C)=O)O[C@@H]1C(C[C@H]([C@@H]([C@H]1O)O)O[C@@H]1[C@@H](CO)O[C@H](OC2C(O[C@@H](OC3[C@@H]([C@@H](NS([O-])(=O)=O)[C@@H]4OC[C@H]3O4)O)[C@H](O)[C@H]2O)C([O-])=O)[C@H](NC(C)=O)[C@H]1C)C([O-])=O)[C@@H]1OC(C([O-])=O)=C[C@H](O)[C@H]1O CIJQTPFWFXOSEO-NDMITSJXSA-J 0.000 description 19
239000003055 low molecular weight heparin Substances 0.000 description 16
229940068196 placebo Drugs 0.000 description 16
239000000902 placebo Substances 0.000 description 16
229920000669 heparin Polymers 0.000 description 15
239000007924 injection Substances 0.000 description 12
238000002347 injection Methods 0.000 description 12
208000010378 Pulmonary Embolism Diseases 0.000 description 10
239000003814 drug Substances 0.000 description 9
230000000694 effects Effects 0.000 description 9
238000011321 prophylaxis Methods 0.000 description 9
206010047249 Venous thrombosis Diseases 0.000 description 8
206010051055 Deep vein thrombosis Diseases 0.000 description 7
206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 7
229940079593 drug Drugs 0.000 description 7
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 6
239000003146 anticoagulant agent Substances 0.000 description 6
229960002897 heparin Drugs 0.000 description 6
229940118179 lovenox Drugs 0.000 description 6
208000007536 Thrombosis Diseases 0.000 description 5
230000009467 reduction Effects 0.000 description 5
238000001356 surgical procedure Methods 0.000 description 5
206010027476 Metastases Diseases 0.000 description 4
238000003745 diagnosis Methods 0.000 description 4
238000000034 method Methods 0.000 description 4
208000011580 syndromic disease Diseases 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
208000032843 Hemorrhage Diseases 0.000 description 3
229940127217 antithrombotic drug Drugs 0.000 description 3
230000009401 metastasis Effects 0.000 description 3
230000035935 pregnancy Effects 0.000 description 3
230000002685 pulmonary effect Effects 0.000 description 3
208000005069 pulmonary fibrosis Diseases 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
239000008215 water for injection Substances 0.000 description 3
206010053567 Coagulopathies Diseases 0.000 description 2
208000035473 Communicable disease Diseases 0.000 description 2
208000001435 Thromboembolism Diseases 0.000 description 2
230000002411 adverse Effects 0.000 description 2
229940127219 anticoagulant drug Drugs 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
229960004969 dalteparin Drugs 0.000 description 2
208000014674 injury Diseases 0.000 description 2
210000003141 lower extremity Anatomy 0.000 description 2
230000014508 negative regulation of coagulation Effects 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
206010043554 thrombocytopenia Diseases 0.000 description 2
230000008733 trauma Effects 0.000 description 2
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
BQSMUQUKNCGJCT-SLPGGIOYSA-N 2-N,6-O-disulfo-D-glucosamine Chemical compound OS(=O)(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](NS(O)(=O)=O)C=O BQSMUQUKNCGJCT-SLPGGIOYSA-N 0.000 description 1
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
206010008111 Cerebral haemorrhage Diseases 0.000 description 1
206010008190 Cerebrovascular accident Diseases 0.000 description 1
206010013654 Drug abuse Diseases 0.000 description 1
206010014666 Endocarditis bacterial Diseases 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
108010074860 Factor Xa Proteins 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
208000034486 Multi-organ failure Diseases 0.000 description 1
206010048591 Post thrombotic syndrome Diseases 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
206010042434 Sudden death Diseases 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
108010000499 Thromboplastin Proteins 0.000 description 1
102000002262 Thromboplastin Human genes 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000036592 analgesia Effects 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
230000002785 anti-thrombosis Effects 0.000 description 1
230000010100 anticoagulation Effects 0.000 description 1
229940030225 antihemorrhagics Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
208000037849 arterial hypertension Diseases 0.000 description 1
208000009361 bacterial endocarditis Diseases 0.000 description 1
230000008901 benefit Effects 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
208000034158 bleeding Diseases 0.000 description 1
231100000319 bleeding Toxicity 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
208000015294 blood coagulation disease Diseases 0.000 description 1
239000003114 blood coagulation factor Substances 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
230000035602 clotting Effects 0.000 description 1
239000002131 composite material Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
230000002254 contraceptive effect Effects 0.000 description 1
229940109239 creatinine Drugs 0.000 description 1
238000009109 curative therapy Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000008260 defense mechanism Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000003205 diastolic effect Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
230000037406 food intake Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
230000000025 haemostatic effect Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
210000003709 heart valve Anatomy 0.000 description 1
208000031169 hemorrhagic disease Diseases 0.000 description 1
230000023597 hemostasis Effects 0.000 description 1
-1 heparin benzyl ester Chemical class 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
201000007119 infective endocarditis Diseases 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
238000009593 lumbar puncture Methods 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000010197 meta-analysis Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
229960000899 nadroparin Drugs 0.000 description 1
230000000399 orthopedic effect Effects 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
235000015277 pork Nutrition 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000011301 standard therapy Methods 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
230000002537 thrombolytic effect Effects 0.000 description 1
230000001732 thrombotic effect Effects 0.000 description 1
238000002627 tracheal intubation Methods 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000003519 ventilatory effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA2654839A 2009-02-20 2009-02-20 Utilisation de l'enoxaparine pour reduire le risque de mortalite chez les patients gravement malades Abandoned CA2654839A1 (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA2654839A CA2654839A1 (fr)	2009-02-20	2009-02-20	Utilisation de l'enoxaparine pour reduire le risque de mortalite chez les patients gravement malades

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA2654839A CA2654839A1 (fr)	2009-02-20	2009-02-20	Utilisation de l'enoxaparine pour reduire le risque de mortalite chez les patients gravement malades

Publications (1)

Publication Number	Publication Date
CA2654839A1 true CA2654839A1 (fr)	2010-08-20

Family

ID=42634722

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2654839A Abandoned CA2654839A1 (fr)	2009-02-20	2009-02-20	Utilisation de l'enoxaparine pour reduire le risque de mortalite chez les patients gravement malades

Country Status (1)

Country	Link
CA (1)	CA2654839A1 (fr)

2009
- 2009-02-20 CA CA2654839A patent/CA2654839A1/fr not_active Abandoned

Legal Events

Date	Code	Title	Description
2014-04-17	FZDE	Dead	Effective date: 20140220

Publication	Publication Date	Title
AU753124B2 (en)	2002-10-10	Dextran formulations and method for treatment of inflammatory joint disorders
Fuji et al.	2008	Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin
Browd et al.	2004	Prophylaxis for deep venous thrombosis in neurosurgery: a review of the literature
Chen et al.	2019	Efficacy and safety of perioperative tranexamic acid in elderly patients undergoing trochanteric fracture surgery: a randomised controlled trial
US20100331746A1 (en)	2010-12-30	Method of using enoxaparin for reducing the risk of death in acutely ill medical patients
JP2014205721A (ja)	2014-10-30	ヒアルロン酸を使用する急性及び過用性の捻挫及び筋違いの治療方法
JPH06329541A (ja)	1994-11-29	糖尿病性腎症治療用スロデキサイド含有医薬
AU2009200642A1 (en)	2010-09-09	Method using enoxaparin for reducing the risk of death in acutely ill medical patients
MacLaughlin et al.	2002	Anaphylactoid reaction to enoxaparin in a patient with deep venous thrombosis
US7157445B2 (en)	2007-01-02	Administration of enoxaparin sodium to patients with severe renal impairment
Hitos et al.	2009	Venous thromboembolism following primary total hip arthroplasty
RU2791373C1 (ru)	2023-03-07	Способ лечения и профилактики рецидива венозного тромбоза после перенесенной новой коронавирусной инфекции
RU2762945C1 (ru)	2021-12-24	Способ антикоагулянтной терапии и профилактики тромботических осложнений у пациентов с тяжелым повреждением головного мозга в хроническом критическом состоянии
US20230338413A1 (en)	2023-10-26	Oral delivery of heparins
US20130101524A1 (en)	2013-04-25	Semuloparin for the extended prevention of a mortality and/or morbidity event in a patient having undergone hip fracture surgery
Xu et al.	2024	Rare acute pulmonary thromboembolism after internal fixation for isolated multiple rib fractures: a case report
TW201212927A (en)	2012-04-01	Semuloparin for use as an antithrombotic treatment in hip replacement surgery with improved safety in terms of clinically relevant bleedings and major bleedings
EP1568372A1 (fr)	2005-08-31	Administration d'énoxaparine sodique à des patients souffrant d'insuffisance rénale sévère
Koval et al.	2000	Treatment Principles
Hull et al.	2000	A randomized trial of the effect of low molecular weight heparin vs. warfarin on mortality in the long-term treatment of proximal vein thrombosis
CN106039309A (zh)	2016-10-26	用于治疗恶性肿瘤造成的胸腔积液的药物组合物及其应用
CN1292793C (zh)	2007-01-03	人尿激肽原酶在制备脓毒症药物中的应用
CN120695028A (zh)	2025-09-26	一种丁甘交联透明质酸钠凝胶及其组合物和制备方法
TW201215397A (en)	2012-04-16	Semuloparin for the prevention of a mortality and/or morbidity event in a patient undergoing major orthopaedic surgery
AU2012203519A1 (en)	2014-01-16	Treatment of cytokine mediated conditions